君实生物股价连续3天下跌累计跌幅6.15%

Group 1 - The core point of the news is that Junshi Biosciences has experienced a decline in stock price, dropping 1.77% to 38.91 CNY per share, with a total market capitalization of 39.949 billion CNY and a cumulative drop of 6.15% over the last three days [1] - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [1] - The company is located in Shanghai and has been publicly listed since July 15, 2020 [1] Group 2 - According to data, the ICBC Credit Suisse Fund has one fund heavily invested in Junshi Biosciences, with the Kexin Medical ETF (588860) reducing its holdings by 344,700 shares, now holding 235,400 shares, which represents 4.15% of the fund's net value [2] - The Kexin Medical ETF has incurred a floating loss of approximately 164,800 CNY today and a total floating loss of 600,200 CNY during the three-day decline [2] - The Kexin Medical ETF was established on August 8, 2024, with a current size of 193 million CNY and has achieved a year-to-date return of 40.82% [2]